Trial Search Results

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborator: Sanofi

Stanford Investigator(s):


  • Drug: Rasburicase


Inclusion Criteria:

   - A diagnosis of hematologic malignancy.

   - Existing hyperuricemia or high risk of developing hyperuricemia of malignancy.

   - The treating clinician plans to treat the patient with rasburicase. A patient is only
   eligible for RASALL if the clinician has already decided to use rasburicase.
   Rasburicase should not be given in order to make a patient eligible for this
   non-therapeutic observational study.

   - No prior exposure to rasburicase or other urate oxidase.

   - A history of asthma or significant allergy.

Exclusion Criteria

   - Wheezing or an active hypersensitivity reaction at entry.

   - Hypersensitivity to Aspergillus proteins.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
LPCH New Patient Coordinator
Not Recruiting